SOLIRIS (eculizumab): The first treatment specifically approved for PNH

Alexion Case Managers: Providing PNH Support

OneSource offers you personal support from a dedicated Alexion Case Manager

Alexion Case Managers: Providing PNH SupportAlexion Case Managers are registered nurses you can call for education about PNH and SOLIRIS® (eculizumab), and for help getting reimbursement, coverage and access.

Your dedicated Alexion Case Manager becomes familiar with you and your specific situation. The Nurse Case Manager will help coordinate information between you, your doctor, and your insurance carrier to help make sure that
 


  • Your initial approvals and treatments happen without delay
     
  • You have information on how to get SOLIRIS during travel or interruption of the normal treatment schedule
     
  • You have information on maintaining SOLIRIS treatment during life changes
    • College, marriage, relocation, retirement
    • Occupation, insurance, or medical status

Call OneSource to get started on SOLIRIS

  • Call OneSource™ at 1.888.SOLIRIS (1.888.765.4747) to speak to an Alexion Case Manager
     
  • The Alexion Case Manager will collect information and explain the OneSource services to you
     
  • You will need to sign and return the consent forms to OneSource (these can be mailed or faxed back to 1.203.699.2000)
     
  • The Alexion Case Manager is then free to help you navigate insurance issues and coordinate other needs that are important to your SOLIRIS treatment plan

You can sign up for OneSource even before your doctor prescribes SOLIRIS.

Please call 1.888.SOLIRIS (1.888.765.4747) to learn more about OneSource.

Next: OneSource & Your Insurance

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.